Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

839 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA. Fuchs M, et al. Among authors: diehl v. Leukemia. 2024 Jan;38(1):160-167. doi: 10.1038/s41375-023-02064-y. Epub 2023 Oct 16. Leukemia. 2024. PMID: 37845285 Free PMC article. Clinical Trial.
A20 binding and inhibitor of nuclear factor kappa B (NF-κB)-1 (ABIN-1): a novel modulator of mitochondrial autophagy.
Merline R, Rödig H, Zeng-Brouwers J, Poluzzi C, Tascher G, Michaelis J, Lopez-Mosqueda J, Rhiner A, Huber LS, Diehl V, Dikic I, Kögel D, Münch C, Wygrecka M, Schaefer L. Merline R, et al. Among authors: diehl v. Am J Physiol Cell Physiol. 2023 Feb 1;324(2):C339-C352. doi: 10.1152/ajpcell.00493.2022. Epub 2022 Nov 28. Am J Physiol Cell Physiol. 2023. PMID: 36440857 Free PMC article.
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
Kreissl S, Voltin CA, Kaul H, Bühnen I, Mettler J, Pabst T, Eichenauer DA, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Kobe C. Kreissl S, et al. Among authors: diehl v. Br J Haematol. 2022 Apr;197(1):e5-e8. doi: 10.1111/bjh.17997. Epub 2021 Dec 20. Br J Haematol. 2022. PMID: 34929056 No abstract available.
The Role of Decorin and Biglycan Signaling in Tumorigenesis.
Diehl V, Huber LS, Trebicka J, Wygrecka M, Iozzo RV, Schaefer L. Diehl V, et al. Front Oncol. 2021 Nov 30;11:801801. doi: 10.3389/fonc.2021.801801. eCollection 2021. Front Oncol. 2021. PMID: 34917515 Free PMC article. Review.
Biglycan: A regulator of hepatorenal inflammation and autophagy.
Schulz M, Diehl V, Trebicka J, Wygrecka M, Schaefer L. Schulz M, et al. Among authors: diehl v. Matrix Biol. 2021 Jun;100-101:150-161. doi: 10.1016/j.matbio.2021.06.001. Epub 2021 Jun 10. Matrix Biol. 2021. PMID: 34118408 Review.
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P; German Hodgkin Study Group. Kreissl S, et al. Among authors: diehl v. Lancet Haematol. 2021 Jun;8(6):e398-e409. doi: 10.1016/S2352-3026(21)00101-0. Lancet Haematol. 2021. PMID: 34048679 Clinical Trial.
Minimized combinatorial CRISPR screens identify genetic interactions in autophagy.
Diehl V, Wegner M, Grumati P, Husnjak K, Schaubeck S, Gubas A, Shah VJ, Polat IH, Langschied F, Prieto-Garcia C, Müller K, Kalousi A, Ebersberger I, Brandts CH, Dikic I, Kaulich M. Diehl V, et al. Nucleic Acids Res. 2021 Jun 4;49(10):5684-5704. doi: 10.1093/nar/gkab309. Nucleic Acids Res. 2021. PMID: 33956155 Free PMC article.
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B. Gillessen S, et al. Among authors: diehl v. Lancet Haematol. 2021 Apr;8(4):e278-e288. doi: 10.1016/S2352-3026(21)00029-6. Lancet Haematol. 2021. PMID: 33770483 Clinical Trial.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A. Borchmann P, et al. Among authors: diehl v. Lancet Oncol. 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. Lancet Oncol. 2021. PMID: 33539742 Clinical Trial.
839 results